Phase II trial of rifaximin in patients with early-stage HER2 positive breast cancer with gastrointestinal toxicities related to pertuzumab-based therapy.
JOURNAL OF CLINICAL ONCOLOGY(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF CLINICAL ONCOLOGY(2023)